Partner/Head Corporate/M&A

Zürich

+41 43 222 38 00

Notable practitioner

German
English
French
Italian


Bar admissions:

Switzerland

Jurisdictions:

Switzerland

Practice areas:

M&A


Oliver is Partner at Wenger Plattner and heads the Practice Group Corporate & Commercial.

He deals primarily with international and national M&A transactions, restructurings and reorganisations, private equity and venture capital transactions and financings. Moreover, he has broad experience in advising shareholders and companies on aspects of contract, commercial and corporate law.

  • Advised AUDI as lead counsel with respect to its entry in Formula 1 as both power unit supplier as well as the takeover of shares in Sauber Group.
  • Advised Saurer Group on all Swiss legal aspects of the sale of three business units to Rieter. The purchase price for the three businesses is EUR 300 million on a cash and debt free basis.
  • Advised the leading healthcare investment firm Healthcare Royalty Management, LLC regarding the negotiation and conclusion of a purchase and sale agreement with ADC Therapeutics SA (all legal and tax aspects), regarding the purchase of revenue participation rights as well as the taking of collateral in the form of a bank account pledge over a locked box bank account for the royalty payments to be made by ADC under the purchase and sale agreement.
  • Advised Blue Water Biotech Inc., NASDAQ: BWV, on all Swiss legal aspects with respect to the acquisition of all shares in Proteomedix AG, a private, commercial-stage diagnostics oncology company. The parties also introduced a new name for the combined Company: Onconetix, Inc.
  • Advised Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities as lead advisor on all legal and tax aspects regarding the acquisition of 100 % of the shares in Lunaphore Technologies SA, a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research.

  • Capital markets: Equity
  • Financial restructuring
  • M&A
  • Private equity
  • Structured finance/securitisation

  • Automotive
  • Consumer goods and services
  • Healthcare
  • Pharma and life sciences
  • Tech and telecoms

  • Zurich Bar Association
  • Swiss Bar Association
  • International Bar Association

  • Dr. iur. (PhD); University of Zurich